Heart rate reduction and longevity in mice

Basic Research in Cardiology

Volumn 110, Issue 2, 2015, Pages 1-9

  Gent, Sabine ^a   Kleinbongard, Petra ^a   Dammann, Philip ^b   Neuhäuser, Markus ^a,c   Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b University School of Medicine   (Germany)

^c Koblenz University of Applied Science   (Germany)

Author keywords

Heart rate; Ivabradine; Life span; Mice

Indexed keywords

IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEART MUSCLE FIBROSIS; HEART RATE; HEART WEIGHT; LIFE EXTENSION; LONGEVITY; MALE; MOUSE; NONHUMAN; SURVIVAL TIME; ANIMAL; C57BL MOUSE; DRUG EFFECTS; HEART; HEART MUSCLE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BENZAZEPINES; CARDIOVASCULAR AGENTS; HEART; HEART RATE; LONGEVITY; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM;

EID: 84921038423     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0460-7     Document Type: Article

References (47)

1. Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ, for the INVEST Investigators (2008) Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 156:241–247. doi:10.1016/j.ahj.2008.02.023
2. Baumhäkel M, Custodis F, Schlimmer N, Laufs U, Böhm M (2010) Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 212:55–62. doi:10.1016/j.atherosclerosis.2010.03.002
3. Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78:547–581
4. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894. doi:10.1016/S0140-6736(10)61259-7
5. Borlak J, Thum T (2003) Hallmarks of ion channel gene expression in end-stage heart failure. Faseb J 17:1592–1608. doi:10.1096/fj.02-0889com
6. Brayton CF, Treuting PM, Ward JM (2012) Pathobiology of aging mice and GEM: background strains and experimental design. Vet Pathol 49:85–105. doi:10.1177/0300985811430696
7. Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D (2006) Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 572:335–346. doi:10.1113/jphysiol.2005.100776
8. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 102:12879–12884. doi:10.1073/pnas.0506001102
9. Castagno D, Petrie MC, Claggett B, McMurray J (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33:1137–1141. doi:10.1093/eurheartj/ehs004
10. Ceylan-Isik AF, Dong M, Zhang Y, Dong F, Turdi S, Nair S, Yanagisawa M, Ren J (2013) Cardiomyocyte-specific deletion of endothelin receptor A rescues aging-associated cardiac hypertrophy and contractile dysfunction: role of autophagy. Basic Res Cardiol 108:335. doi:10.1007/s00395-013-0335-3
11. Chiao YA, Ramirez TA, Zamilpa R, Okoronkwo SM, Dai Q, Zhang J, Jin YF, Lindsey ML (2012) Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 96:444–455. doi:10.1093/cvr/cvs275
12. Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, Entman ML (2010) Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 50:248–256. doi:10.1016/j.yjmcc.2010.10.019
13. Coburn AF, Grey RM, Rivera SM (1971) Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse. Johns Hopkins Med J 128:169–193
14. Colman RJ, Beasley TM, Kemnitz JW, Johnson SC, Weindruch R, Anderson RM (2014) Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat Commun. doi:10.1038/ncomms4557
15. Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM (2010) Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 159:612–619. doi:10.1016/j.ahj.2009.12.029
16. Cullington D, Goode KM, Clark AL, Cleland JGF (2012) Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail 14:737–747. doi:10.1093/eurjhf/hfs060
17. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:2377–2387. doi:10.1161/CIRCULATIONAHA.107.746537
18. Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983. doi:10.1016/j.jacc.2010.09.014
19. Du X-J, Feng X, Gao X-M, Tan TP, Kiriazis H, Dart AM (2004) If channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol 142:107–112. doi:10.1038/sj.bjp.0705696
20. Ferrari R (2012) The story of the heartbeat, continued. Eur Heart J 33:288–289
21. Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71–82. doi:10.1001/jama.2012.113905
22. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, for the Heart Rate Working Group (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50:823–830. doi:10.1016/J.Jacc.2007.04.079
23. Gordon LB, Massaro J, D’Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW, the Progeria Clinical Trials Collaborative (2014) Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 130:27–34. doi:10.1161/CIRCULATIONAHA.113.008285
24. Hanumanthappa NB, Madhusudan G, Mahimarangaiah J, Manjunath CN (2011) Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis. Ann Pediatr Cardiol 4:204–206. doi:10.4103/0974-2069.8467
25. Heusch G (2008) Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153:1589–1601. doi:10.1038/sj.bjp.0707673
26. Heusch G (2008) Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol 155:970–971. doi:10.1038/bjp.2008.347
27. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R (2008) Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine—protection beyond heart rate reduction. Eur Heart J 29:2265–2275. doi:10.1093/eurheartj/ehn337
28. Hilzendeger AM, Goncalves AC, Plehm R, Diedrich A, Gross V, Pesquero JB, Bader M (2010) Autonomic dysregulation in ob/ob mice is improved by inhibition of angiotensin-converting enzyme. J Mol Med 88:383–390. doi:10.1007/s00109-009-0569-6
29. Jiang J, Tian L, Huang Y, Li Y, Xu L (2013) Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clin Ther 35:1933–1945. doi:10.1016/j.clinthera.2013.10.007
30. Lane PW, Dickie MM (1958) The effect of restricted food intake on the life span of genetically obese mice. J Nutr 64:549–554
31. Lee JF, Harrison ML, Christmas KM, Kim K, Hurr C, Brothers RM (2014) Elevated resting heart rate and reduced orthostatic tolerance in obese humans. Clin Auton Res 24:39–46. doi:10.1007/s10286-013-0222-x
32. Levine HJ (1997) Rest heart rate and life expectancy. J Am Coll Cardiol 30:1104–1106. doi:10.1016/S0735-1097(97)00246-5
33. Liu J, Sirenko S, Juhaszova M, Sollott SJ, Shukla S, Yaniv Y, Lakatta EG (2014) Age-associated abnormalities of intrinsic automaticity of sinoatrial nodal cells are linked to deficient cAMP-PKA-Ca(2+) signaling. Am J Physiol Heart Circ Physiol 306:H1385–H1397. doi:10.1152/ajpheart.00088.2014
34. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R (2012) Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev 11:390–398. doi:10.1016/j.arr.2011.11.005
35. Nanchen D, Leening MJ, Locatelli I, Cornuz J, Kors JA, Heeringa J, Deckers JW, Hofman A, Franco OH, Stricker BH, Witteman JC, Dehghan A (2013) Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study. Circ Heart Fail 6:403–410. doi:10.1161/CIRCHEARTFAILURE.112.000171
36. Neuhäuser M (2012) Nonparametric statistical tests: a computational approach. CRC Press, Chapman & Hall, New York
37. Rich MW, McSherry F, Williford WO, Yusuf S, for the Digitalis Investigation Group (2001) Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813. doi:10.1016/S0735-1097(01)01442-5
38. Robinson RB, Siegelbaum SA (2003) Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 65:453–480. doi:10.1146/annurev.physiol.65.092101.142734
39. Rogowski O, Steinvil A, Berliner S, Cohen M, Saar N, Ben-Bassat OK, Shapira I (2009) Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol 8:55. doi:10.1186/1475-2840-8-55
40. Rohrbach S, Aslam M, Niemann B, Schulz R (2014) Impact of caloric restriction on myocardial ischemia/reperfusion injury and new therapeutic options to mimic its effects. Br J Pharmacol. doi:10.1111/bph.12650
41. Ruxton GD, Neuhäuser M (2010) When should we use one-tailed hypothesis testing? Methods Ecol Evol 1:114–117. doi:10.1111/j.2041-210X.2010.00014.x
42. Schulz R, Aker S, Belosjorow S, Konietzka I, Rauen U, Heusch G (2003) Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits. Am J Physiol Heart Circ Physiol 285:H2084–H2090. doi:10.1152/ajpheart.01038.2002
43. Stessman J, Jacobs JM, Stessman-Lande I, Gilon D, Leibowitz D (2013) Aging, resting pulse rate, and longevity. J Am Geriatr Soc 61:40–45. doi:10.1111/jgs.12060
44. Storer JB (1966) Longevity and gross pathology at death in 22 inbred mouse strains. J Gerontol 21:404–409. doi:10.1093/geronj/21.3.404
45. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885. doi:10.1016/S0140-6736(10)61198-1
46. Yashin AI, Akushevich IV, Arbeev KG, Akushevich L, Ukraintseva SV, Kulminski A (2006) Insights on aging and exceptional longevity from longitudinal data: novel findings from the Framingham Heart Study. Age 28:363–374. doi:10.1007/s11357-006-9023-7
47. Zhang GQ, Zhang W (2009) Heart rate, lifespan, and mortality risk. Ageing Res Rev 8:52–60. doi:10.1016/j.arr.2008.10.001